Rights and permissions
About this article
Cite this article
Paclitaxel + cisplatin cost-effective option in ovarian cancer. Pharmacoecon. Outcomes News 107, 8 (1997). https://doi.org/10.1007/BF03271487
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03271487